CONTEXT: The relationship of monocyte/macrophage activation to insulin resistance in obesity is unknown. OBJECTIVE: To investigate a marker of macrophage activation, soluble CD163 (sCD163), in relationship to insulin resistance and metabolic parameters in obese and normal-weight subjects. DESIGN AND PARTICIPANTS: Ninety-five healthy subjects (65 obese and 30 normal-weight) were studied. Plasma concentrations of sCD163 were assessed, as well as markers of glucose homeostasis, anthropometrics, cytokines and adipokines. The relationships between sCD163 and these parameters were investigated, and multiple regression modelling assessing the contribution of sCD163 to insulin resistance (HOMA-IR) was performed. RESULTS: Soluble CD163 was significantly increased in obese subjects compared with normal-weight controls [974 (657, 1272) ng/ml vs 599 (423, 892) ng/ml, median (IQR); P < 0·0001]. sCD163 was strongly associated with HOMA-IR (Spearman's ρ = 0·37, P = 0·0003) and other metabolic parameters. In multiple regression modelling for log HOMA-IR, sCD163 remained significantly associated (P = 0·005) controlling for known mediators of insulin resistance including age, gender, visceral adiposity and inflammatory markers (model R(2) = 0·54, P < 0·0001). Additional nested multiple regression models for log HOMA-IR showed that sCD163 added more than other adipokines and inflammatory markers to the prediction of HOMA-IR. CONCLUSIONS: Monocyte/macrophage activation, as reflected by sCD163 levels, is strongly associated with HOMA-IR in normal-weight and obese subjects after controlling for known mediators of insulin resistance. Moreover, sCD163 adds to standard risk markers for predicting insulin resistance. These data suggest that monocyte/macrophage activation may be an important determinant of insulin resistance in obesity.
CONTEXT: The relationship of monocyte/macrophage activation to insulin resistance in obesity is unknown. OBJECTIVE: To investigate a marker of macrophage activation, soluble CD163 (sCD163), in relationship to insulin resistance and metabolic parameters in obese and normal-weight subjects. DESIGN AND PARTICIPANTS: Ninety-five healthy subjects (65 obese and 30 normal-weight) were studied. Plasma concentrations of sCD163 were assessed, as well as markers of glucose homeostasis, anthropometrics, cytokines and adipokines. The relationships between sCD163 and these parameters were investigated, and multiple regression modelling assessing the contribution of sCD163 to insulin resistance (HOMA-IR) was performed. RESULTS: Soluble CD163 was significantly increased in obese subjects compared with normal-weight controls [974 (657, 1272) ng/ml vs 599 (423, 892) ng/ml, median (IQR); P < 0·0001]. sCD163 was strongly associated with HOMA-IR (Spearman's ρ = 0·37, P = 0·0003) and other metabolic parameters. In multiple regression modelling for log HOMA-IR, sCD163 remained significantly associated (P = 0·005) controlling for known mediators of insulin resistance including age, gender, visceral adiposity and inflammatory markers (model R(2) = 0·54, P < 0·0001). Additional nested multiple regression models for log HOMA-IR showed that sCD163 added more than other adipokines and inflammatory markers to the prediction of HOMA-IR. CONCLUSIONS: Monocyte/macrophage activation, as reflected by sCD163 levels, is strongly associated with HOMA-IR in normal-weight and obese subjects after controlling for known mediators of insulin resistance. Moreover, sCD163 adds to standard risk markers for predicting insulin resistance. These data suggest that monocyte/macrophage activation may be an important determinant of insulin resistance in obesity.
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: Hideo Makimura; Takara Stanley; David Mun; Cindy Chen; Jeffrey Wei; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: D Sporrer; M Weber; J Wanninger; J Weigert; M Neumeier; F Stögbauer; E Lieberer; M Bala; A Kopp; A Schäffler; C Buechler Journal: Eur J Clin Invest Date: 2009-05-21 Impact factor: 4.686
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: J E Lake; G A McComsey; T Hulgan; C A Wanke; A Mangili; S L Walmsley; S A Stramotas; R Tracy; J S Currier Journal: HIV Med Date: 2014-02-10 Impact factor: 3.180
Authors: Chris T Longenecker; Seunghee Margevicius; Yiying Liu; Mark D Schluchter; Chun-Ho Yun; Hiram G Bezerra; Grace A McComsey Journal: Am J Cardiol Date: 2017-07-24 Impact factor: 2.778
Authors: Chris T Longenecker; Ying Jiang; Chun-Ho Yun; Sara Debanne; Nicholas T Funderburg; Michael M Lederman; Norma Storer; Danielle E Labbato; Hiram G Bezerra; Grace A McComsey Journal: Int J Cardiol Date: 2013-07-22 Impact factor: 4.164
Authors: Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl Journal: Future Virol Date: 2013-01 Impact factor: 1.831